Sumanta K. Pal, MD, FASCO, on Tolerability of Lenvatinib and Everolimus to Treat Patients With RCC

Video

Pal detailed the phase 2 trial of lenvatinib at 2 starting doses plus everolimus to treat patients with renal cell carcinoma.

Sumanta K. Pal, MD, FASCO, spoke with CancerNetwork® to detail a phase 2 trial (NCT03173560) of lenvatinib (Lenvima) at 2 starting doses and everolimus to treat patients with renal cell carcinoma, discussing challenges with tolerability of the drugs from a presentation at the 2021 Genitourinary Cancers Symposium.

Transcription:

This particular combination with lenvatinib and everolimus doesn’t include an [immunotherapy] component, it’s just pure targeted therapy. And I would suggest that, in terms of tolerability, it has its challenges. I was hoping that perhaps we could get away with using a lower dose and thereby mitigate some toxicity, but it doesn’t appear that that’s the case. It certainly does suggest to me that perhaps there are challenges as we try to implement the higher dose of lenvatinib with pembrolizumab. [In the CLEAR study (NCT02811861)], they use a dose of 20 mg of lenvatinib, but I can't imagine that that's going to be any easier for patients.

Reference:

Pal SK, Puente J, Heng DYK, et al. Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI). Presented at: 2021 Genitourinary Cancers Symposium. Abstract 307.

Recent Videos
Noah S. Kalman, MD, MBA, describes the rationale for using a test to measure granular details of taste change in patients undergoing radiotherapy for HNC.
No evidence indicates synergistic toxicity when combining radiation with CAR T-cell therapy in this population, according to Timothy Robinson, MD, PhD.
The addition of radiotherapy to CAR T-cell therapy may particularly benefit patients with localized disease, according to Timothy Robinson, MD, PhD.
Timothy Robinson, MD, PhD, discusses how radiation may play a role as bridging therapy to CAR T-cell therapy for patients with relapsed/refractory DLBCL.
James Ninia, MD, discussed treatment options for patients with extensive-stage small cell lung cancer undergoing metastasis-directed radiotherapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
A review of patients with metastatic clear cell renal cell carcinoma shows radiological tumor burden as an independent prognostic factor for survival.
A phase 2 trial is assessing ubamatamab in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma.
Related Content